2023 World Conference on Lung Cancer (Posters)-EP06.03. The Prognostic Impact of Postoperative EGFR Mutation Status in Lung Cancer Patients with Stage II - III

EP06.03. The Prognostic Impact of Postoperative EGFR Mutation Status in Lung Cancer Patients with Stage II - III - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to assess the occurrence of epidermal growth factor receptor (EGFR) mutation in patients with stage II-III lung adenocarcinoma who had undergone surgical resection. The study included 194 patients diagnosed with non-small cell lung cancer between 2007 and 2016. The frequency of EGFR mutations, as well as disease-free survival (DFS) and overall survival (OS), were analyzed.<br /><br />The results showed that 34% of the patients had EGFR mutations, while 66% did not. The 5-year overall and disease-free survival rates for the entire group were 61.9% and 45.4%, respectively. However, the occurrence of EGFR mutation did not have a significant influence on OS and DFS in patients after surgical resection.<br /><br />Further analysis was conducted to assess the impact of adjuvant therapy on survival. It was found that adjuvant therapy did not significantly affect DFS or OS in the EGFR mutation-positive group. The study suggests that patients with EGFR mutations may benefit more from novel adjuvant therapies such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) rather than cisplatin-based chemotherapy.<br /><br />In conclusion, the frequency of EGFR mutation in postoperative lung cancer was similar to that in the general lung cancer population. However, EGFR mutation did not have a significant impact on survival in patients after resection. The study highlights the potential for novel adjuvant therapies in improving outcomes for patients with EGFR mutations.

Asset Subtitle

Shota Nakamura

Meta Tag

Speaker Shota Nakamura

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

epidermal growth factor receptor mutation

lung adenocarcinoma

surgical resection

non-small cell lung cancer

disease-free survival

overall survival

adjuvant therapy

tyrosine kinase inhibitors

immune checkpoint inhibitors

cisplatin-based chemotherapy